125.1 ð é«åžçç
125.1.0.1 ð äžé éé»
- ç åèŽç 忥: (1) Encounter, (2) Entry, (3) Spread, (4) Multiplication
- Virulence factors: adherence (pili, fimbriae), invasion (invasins), toxin (exo/endo), immune evasion (capsule, antigenic variation)
- Endotoxin (LPS) vs Exotoxin â ç¶å ž Gram - é°æ§ vs é°éœå ©æŽŸ
- Quorum sensing: bacterial communication â biofilm formation
- Pathogenicity Island: åºå 矀線碌 virulence
125.1.0.2 1ïžâ£ Adherence (éè)
ð äžææŠå¿µèªªæïŒéèæ¯ææçç¬¬äžæ¥ïŒæ²æé»äžå°±æ²æåŸçºãèšåºæçŸ©ïŒèš±å€ç«è (äŸåŠ acellular pertussis å« FHAãUPEC ç«è詊é©) èæ°è¥éœçæº adhesin 黿·ææèµ·å§ãGram - å€çš pili/fimbriaeïŒçްé·è¡šé¢çªèµ·ãèç³éåé«å°äžçµåïŒïŒGram + å€çšè¡šé¢èçœ adhesin (S. aureus protein AãS. pyogenes M protein)ãç¹ç°æ§æ±ºå® tissue tropism â çºä»éºŒ UPEC å奜èè±ãN. gonorrhoeae åå¥œçæ®æ³å°¿ãH. pylori å奜èé»èïŒéœæ¯ adhesin à receptor å°ææ±ºå®ã
- Pili / Fimbriae (Gram - bacteria): è宿䞻现è receptor çµå
- N. gonorrhoeae: type IV pili â urogenital epithelium
- E. coli (UPEC): P pili â uroepithelium
- H. pylori: BabA â Lewis b antigen on gastric epithelium
- Adhesins (Gram + ): protein A (S. aureus), M protein (S. pyogenes)
125.1.0.3 2ïžâ£ Toxins â Exotoxin vs Endotoxin
ð äžææŠå¿µèªªæïŒExotoxin æ¯ã粟æºå°åœãïŒç¹å® receptor + ç¹å® organ damageïŒå¯ä»¥åæ toxoid ç«è (diphtheriaãtetanus å°±æ¯ toxoid ç«èçæåå žç¯)ïŒEndotoxin (LPS) æ¯ã廣èççžãïŒæ¯ææ Gram - å€èç Lipid A çµæ§ïŒäžèœå toxoid (å€ªå€ Gram - å ±æ)ïŒèšåºäžçå°ç septic shock cytokine storm äž»å ãèšåºæ±ºç圱é¿ïŒ(1) 被 exotoxin ä»å°ççŸç èŠäžåæ¯çŽ èéåªæ®ºè â äŸåŠç Žå·é¢šèŠæ TIG (人é¡ç Žå·é¢šå ç«çèçœ)ãèæ¯æ¡¿èäžæ¯èŠæææ¯çŽ è¡æž ãçœåèŠæ DAT ææ¯çŽ ïŒæççŽ åªæ¯èŒå©ãæ¯çŽ äžåææåœïŒ(2) endotoxin åŒèµ·ç septic shock æ²æãææ¯çŽ ãïŒåªèœ supportive (fluid + vasopressor + source control) + æççŽ æ®ºèæžå° LPS éæŸïŒå ¶å¯Šæ®ºèç¬éå¯èœéæŸæŽå€ LPSïŒéå°±æ¯ Jarisch-Herxheimer åæ èæ¢ æ¯/borreliosis æ²»çåææ¡åçæ©å¶ïŒã
| ç¹åŸµ | Exotoxin | Endotoxin (LPS) |
|---|---|---|
| äŸæº | Gram +/- secreted protein | Gram - outer membrane |
| çµæ§ | Protein | Lipopolysaccharide (Lipid A æ¯æŽ»æ§) |
| ç±ç©© | éåžž heat-labile | Heat-stable |
| æåæ§ | é« (toxoid â vaccine) | äœ |
| Receptor | Specific cell receptor | TLR4-CD14 â cytokine cascade |
| çµæ | ç¹å® organ damage | å šèº« SIRS, septic shock |
| ç¶å žä»£è¡š | Diphtheria, tetanus, botulinum, cholera | E. coli, N. meningitidis, Pseudomonas |
125.1.0.3.1 ç¶å ž Exotoxins
| Toxin | äŸæº | æ©èœ |
|---|---|---|
| Diphtheria toxin | C. diphtheriae | ADP-ribosylation of EF-2 â èçœåæå |
| Tetanus toxin (TeNT) | C. tetani | Cleave synaptobrevin â block GABA/glycine release â spastic paralysis |
| Botulinum toxin (BoNT) | C. botulinum | Cleave SNARE â block ACh release â flaccid paralysis |
| Cholera toxin | V. cholerae | ADP-ribosylation of Gs â cAMP â â Cl- secretion â watery diarrhea |
| Shiga toxin | Shigella, E. coli O157:H7 | Inactivate 60S ribosome â cell death â HUS |
| Pertussis toxin | B. pertussis | ADP-ribosylation of Gi â cAMP â â lymphocytosis |
| Anthrax toxin | B. anthracis | Edema factor (cAMP), Lethal factor (MAPK) |
| TSST-1 | S. aureus | Superantigen â massive T cell activation â toxic shock |
125.1.0.4 3ïžâ£ Immune Evasion
ð äžææŠå¿µèªªæïŒå ç«èº²é¿æ¯æ ¢æ§ææèéçææçééµãè¢è (capsule) æ¯åå¬çްèçãæ»æºå€è¡£ãïŒæä»¥æè¢èç现èç¹å¥æåš asplenic ç äººé æ overwhelming sepsis â é乿¯èŸåé€åèŠæ pneumococcal / meningococcal / Hib äžå€§ç«èçåå ïŒèšæ¶å£èš£ KENPNS (K. pneumoniaeãE. coli K1ãN. meningitidisãPneumococcusãH. influenzae bãN. gonorrhoeae éšåæ ªãSalmonella typhi Vi) æ¯åèé«é »ãæåè®ç°æ¯æµææ¯å¹ŽèŠæç«è (antigenic drift) è倧æµè¡ (antigenic shift) çæ©å¶ïŒçްèå §èå¿æ¯ TB çºä»éºŒèŠæ 6 åæãçºä»éºŒ latent TB èŠ 3-9 åæ isoniazid é é²çæ ¹æ¬åå â bacilli èº²åš macrophage å §ïŒè¥ç©èŠèœç©¿éæææã
- Capsule (S. pneumoniae, N. meningitidis, H. influenzae b, Klebsiella) â æ phagocytosis
- Protein A (S. aureus) â bind IgG Fc â 黿¢ opsonization
- IgA protease (N. gonorrhoeae, S. pneumoniae) â cleave mucosal IgA
- Antigenic variation (Influenza, HIV, N. gonorrhoeae, Trypanosoma)
- Intracellular hiding (M. tuberculosis, Salmonella, Listeria, Legionella)
125.1.0.5 4ïžâ£ Quorum Sensing + Biofilm
ð äžææŠå¿µèªªæïŒBiofilm æ¯èšåºé£æ²»ææçæå€§å æãä»»äœç眮è£çœ® (catheterãprosthetic jointãprosthetic valveãCSF shuntãpacemaker leadãIV line) äžé·åº biofilm åŸïŒæççŽ MIC å¯äžå 100-1000 å â å çº matrix 黿è¥ç©æ»²é + biofilm å §çŽ°è代è¬éäœ (persister cells)ãèšåºéµåïŒbiofilm ææå¿ é ç§»é€ foreign bodyïŒå é å»¶é·æççŽ æäžæãQuorum sensing æ¯ biofilm 圢æçééïŒæ°è¥ç ç©¶æ¹åå°±æ¯é»æ· quorum sensing 鲿¢ biofilm 圢æïŒäœç®åéæ²æ FDA æ žåç anti-quorum-sensing è¥ç©äžåžãç¶å žèšåºæ å¢ïŒPJI (prosthetic joint infection)ãIE on prosthetic valveãCRBSI (catheter-related bloodstream infection)ãCF ç äººæ ¢æ§ Pseudomonas 宿€ã
- Quorum sensing: 现èç¶ç± small molecule (autoinducer) 嵿ž¬æçŸ€å¯åºŠ â åå virulence genes
- Biofilm: matrix-encapsulated bacterial community on surface
- æ antibiotics (100-1000Ã MIC)
- æ host immune
- ç¶å ž: catheter, prosthetic joint, endocarditis vegetation, cystic fibrosis Pseudomonas
- Treatment: ç§»é€ foreign body (catheter), é«åé antibiotics, anti-biofilm agents